Tag Archives: Ram Selvaraju

Foamix Pharma (FOMX) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Foamix Pharma (FOMX – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $3.16. According to TipRanks.com, Selvaraju is currently ranked with

H.C. Wainwright Reaffirms Their Buy Rating on Kezar Life Sciences Inc (KZR)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences Inc (KZR – Research Report), with a price target of $15.00. The company’s shares closed last Monday at $3.53, close to its

Evofem Biosciences Inc (EVFM) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Evofem Biosciences Inc (EVFM – Research Report), with a price target of $9.00. The company’s shares closed last Monday at $5.01. According to TipRanks.com, Selvaraju

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics Inc (NASDAQ: AXSM) and TherapeuticsMD (NASDAQ: TXMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics Inc (AXSM – Research Report) and TherapeuticsMD (TXMD – Research Report) with bullish sentiments. Axsome Therapeutics Inc (AXSM) In a

Abeona Therapeutics (ABEO) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report) today and set a price target of $15.00. The company’s shares closed last Monday at $2.71, close to its 52-week low of $1.46. According

H.C. Wainwright Sticks to Its Buy Rating for Protalix Biotherapeutics (PLX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Protalix Biotherapeutics (PLX – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $0.21, close to its 52-week low